ANXA2 and acute myeloid leukemia: For example, circ-ANXA2 is highly expressed in AML, and patients with higher circ-ANXA2 levels exhibit shorter overall survival (OS) and event-free survival (EFS), poorer risk profiles, and a lower probability of complete remission (CR) [74].